Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dannon class-action suit

This article was originally published in The Tan Sheet

Executive Summary

Class-action lawsuit against yogurt-maker Dannon alleges the firm makes false advertising claims for probiotic-containing products Activia and DanActive. Filed Jan. 23 in a Los Angeles federal court, the suit alleges Dannon's claims that probiotics help regulate digestion and boost immunity lack scientific substantiation and are therefore false. In a Jan. 24 press release, the White Plains, N.Y.-based firm says it "strongly disagrees with the allegations in the lawsuit" and is reviewing the case. In addition, the firm adds: "All of Dannon's claims for Activia and DanActive are completely supported by peer-reviewed science and are in accordance with all laws and regulations. Dannon's advertising has always been and will continue to be absolutely truthful, and Dannon will vigorously challenge this lawsuit." In 2006 the National Advertising Division determined claims for Activia were substantiated (1"The Tan Sheet" Aug. 7, 2006, p. 13)...

You may also be interested in...

Dannon's DanActive And Activia Not Immune To Health Claim Scrutiny

A class-action lawsuit against Dannon, resulting in a $35 million settlement, could open the door to additional "nuisance" suits over functional food claims, one food and drug attorney says

Dannon’s “Naturally Regulates Digestive Tract” Claim Reviewed By NAD

A television ad for Dannon Activia yogurt should clarify that the product's benefits apply to bloating and irregularity, as opposed to the chronic condition of constipation, according to a recent ruling by the National Advertising Division

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts